Respiratory sales

Quote

anonymous

Guest
I have an upcoming interview for a Respiratory sales role. Can someone please give me a lay of the land? Expected comp, car choice, viability of product line, management, etc. Thank you
 

anonymous said:
I have an upcoming interview for a Respiratory sales role. Can someone please give me a lay of the land? Expected comp, car choice, viability of product line, management, etc. Thank you
Click to expand...

If you are on Cafepharma asking about the product line then you have no business being in this business. Do you even Google, bro?
 
anonymous said:
Google doesn’t always give you an accurate depiction of what is really going on, especially with a new product launch. Do you even understand the question, bro?
Click to expand...

You get a lot of buttheads on here that give you grief for wanting more detailed information than you can google. If you wait long enough, sometimes someone will come on who is helpful. I don't work here, but I work in respiratory. Generic Advair will be a huge hit if they price it right. A generic only has to be 10% less than the brand, so they may be too high until another player comes into the market. It will thud like a turd if it is too expensive. The company makes me nervous because of their track record with Epipen. If you don't have a current gig it could be really great. Good luck with the trolls.
 
What once looked to be a great achievement has turned into another colossal failure!

  1. The Mylan device doesn't resemble the Advair Diskus and is complicated for patients to use.
  2. GSK was prepared and just received an AB generic approval by the FDA.
  3. GSK has locked in managed care contracts for another year
  4. This means that what were to be billions in sales will actually only be around 250 million.
Mylan was hell bent on this but was outsmarted by GSK. Guess it's time to jack up the price on our epi-pen again.
 
anonymous said:
You get a lot of buttheads on here that give you grief for wanting more detailed information than you can google. If you wait long enough, sometimes someone will come on who is helpful. I don't work here, but I work in respiratory. Generic Advair will be a huge hit if they price it right. A generic only has to be 10% less than the brand, so they may be too high until another player comes into the market. It will thud like a turd if it is too expensive. The company makes me nervous because of their track record with Epipen. If you don't have a current gig it could be really great. Good luck with the trolls.
Click to expand...

How’s the first couple weeks of sales going?
 
anonymous said:
What once looked to be a great achievement has turned into another colossal failure!

  1. The Mylan device doesn't resemble the Advair Diskus and is complicated for patients to use.
  2. GSK was prepared and just received an AB generic approval by the FDA.
  3. GSK has locked in managed care contracts for another year
  4. This means that what were to be billions in sales will actually only be around 250 million.
Mylan was hell bent on this but was outsmarted by GSK. Guess it's time to jack up the price on our epi-pen again.
Click to expand...

Wait a minute. I don’t work at Mylan, but know a little about this. How could the device not resemble the diskus? It HAS to in order to be AB rated. It can have “tweaks,” but must have the same chassis.

If GSK came out with a generic, that’s called an “authorized generic.” Pretty much all brands do that now. The fact that they did this tells me that they don’t expect to hold on to substantial branded share for that long.

The brand ALWAYS maintains a favorable formulary position, via contracting, against the generic unless or until 2 generics launch. Then, generics will move into 1st tier on formularies. It usually takes 6 months post generic launch. Then, The large retail pharmacies will switch the brand to generic at the pharmacy level because it makes them more money, regardless of payor-manufacturer contracts.

In 4 quarters, the brand will have 20% share left. You saw it here first.
 
So Wixela took off vs. GSK's generic since WAC was so cheap, yet AWP was close to others. That means there is an inherent desire by retail pharmacies to fill Wixela since they get reimbursed based on AWP making a ton per RX. This is a problem for Med D patients since most Med D MCO's aren't covering the drug yet meaning if patient actually fills the RX, the cost is huge. We saw a very pronounced uptick and now a decrease in Med D since patients will not pay the price.
This isn't the case for commercial however where we are capturing a lot.

Also, the devise is not exactly the same as the diskus. I have heard from some offices that patients (more COPD) do not like it. Say they aren't getting the same effect and that they cough a lot. Can only assume it is based on particle size, higher PIFr needed or both.
 
I think the question was which brands (not generic) are still being promoted by the team.
If there is link that shows this that I am missing then just let me know.
Thanks!
 
anonymous said:
I think the question was which brands (not generic) are still being promoted by the team.
If there is link that shows this that I am missing then just let me know.
Thanks!
Click to expand...

I’m sorry. Were you under the impression that Mylan is a branded manufacturer? It is not.
It had a couple brands, but you would be selling the concept of bioequivalence to doctors to get them to understand that it’s ok to allow the generic switch to go through at the pharmacy level. Not to write “brand necessary.” Drop of co-pay program info. Whatever they need you to do. Maybe some biosimilars, but just selling the concept there where they are not AB rated.
 


Write your reply...
Top Bottom
Back
Quote